Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Baxter

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

AUGMENTIN XR Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Augmentin Xr patents expire, and when can generic versions of Augmentin Xr launch?

Augmentin Xr is a drug marketed by Neopharma and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-six patent family members in forty-eight countries.

The generic ingredient in AUGMENTIN XR is amoxicillin; clavulanate potassium. There are forty-six drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.

Drug patent expirations by year for AUGMENTIN XR
Drug Prices for AUGMENTIN XR

See drug prices for AUGMENTIN XR

Recent Clinical Trials for AUGMENTIN XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Georgetown UniversityEarly Phase 1
National Center for Complementary and Integrative Health (NCCIH)Early Phase 1
University of MarylandEarly Phase 1

See all AUGMENTIN XR clinical trials

Synonyms for AUGMENTIN XR
2C16H19N3O5S.C8H8NO5.K
74428-36-7
74469-00-4
79198-29-1 (parent)
Amocla
Amoclan
Amoclav
Amoxi-Clavulanate
Amoxicillin / clavulanic acid
AMOXICILLIN AND CLAVULANATE POTASSIUM
Amoxicillin clavulanate potassium
Amoxicillin mixed with potassium clavulanate (2:1)
Amoxicillin mixture with Clavulanate potassium
Amoxicillin-Clavulanic Acid
Amoxicillin-potassium clavulanate combination
AMOXICILLIN; CLAVULANATE POTASSIUM
Amoxsiklav
Amoxycillin-Clavulanic Acid
Ancla
Augmentan
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
Augmentin (antibiotic)
Augmentin ES-600
Augmentine
Auspilic
BRL 25000
BRL 25000A
BRL 25000G
BRL-25000
CHEMBL1697738
Clamentin
Clamobit
Clavam 625
Clavamox
Clavinex
Clavoxilin Plus
Clavulanate Potentiated Amoxycillin
Clavulin
Clavumox
Co-amoxiclav
Coamoxiclav
DTXSID40225477
DWHGNUUWCJZQHO-ZVDZYBSKSA-M
Eumetinex
Kmoxilin
LS-187831
LS-98547
Potassium clavulanate mixed with amoxicillin (1:2)
Potassium Clavulanate-Amoxicillin Combination
SCHEMBL240728
Spectramox
Spektramox
Viaclav
Xiclav

US Patents and Regulatory Information for AUGMENTIN XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for AUGMENTIN XR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 1000 mg/62.5 mg ➤ Subscribe   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Harvard Business School
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.